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ABSTRACT
Objective: In patients who have undergone a
potentially curative resection of colorectal cancer, does
a ‘second-look’ operation to resect recurrence,
prompted by monthly monitoring of carcinoembryonic
antigen, confer a survival benefit?
Design: A randomised controlled trial recruiting
patients from 1982 to 1993 was recovered under the
Restoring Invisible and Abandoned Trials (RIAT)
initiative.
Setting: 58 hospitals in the UK.
Participants: From 1982 to 1993, 1447 patients were
enrolled. Of these 216 met the criteria for
carcinoembryonic antigen (CEA) elevation and were
randomised to ‘Aggressive’ or ‘Conventional’ arms.
Interventions: ‘Second-look’ surgery with intention to
remove any recurrence discovered.
Primary outcome measure: Survival.
Results: By February 1993, 91/108 patients had died
in the ‘Aggressive arm’ and 88/108 in the
‘Conventional’ arm (relative risk=1.16, 95% CI 0.87 to
1.37). By 2011 a further 25 randomised patients had
died. Kaplan-Meier analysis showed no difference in
long-term survival.
Conclusions: The trial was closed in 1993 following a
recommendation from the Data Monitoring Committee
that it was highly unlikely that any survival advantage
would be demonstrated for CEA prompted second-look
surgery. This conclusion was confirmed by repeat
analysis of survival times after 20 years.
Trial registration number: ISRCTN76694943.
INTRODUCTION
The Working Party of the carcinoembryonic
antigen (CEA) Second-Look Trial set the
scene for their trial in their protocol in
1982 (Slack W, Bagshawe K, Baum M, et al.
Protocol: a multicentre trial to evaluate the
use of serial carcinoembryonic antigen assay
as the prime indicator for second-look
surgery in recurrent colorectal cancer (Trial
Archive), 1982, unpublished work). The
principal ﬁnding, that CEA monitoring to
detect asymptomatic recurrence was not asso-
ciated with improved survival, was
announced in a letter to the Journal of the
American Medical Association in 1994 by
Northover, the then chief investigator.1 The
writing of the trial for publication lapsed. We
here report the trial under the Restoring
Invisible and Abandoned Trials (RIAT)
initiative.2 3
It had been observed during the 1970s that
the outlook for patients with colorectal
cancer was not good. Only one in four
patients survived for 5 years after diagnosis
and radical surgery was observed to be
Strengths and limitations of this study
▪ The carcinoembryonic antigen (CEA) Second-
Look Trial was a well-planned and carefully
executed study with a clear question and a well-
defined outcome of interest.
▪ Second-look surgery prompted by the best avail-
able indicator of recurrence at the time conferred
no survival advantage.
▪ A further strength, and a reason to publish this
trial now, is that it shows that randomised trials
in surgery can be carried out and that the result
may be contrary to the beliefs and expectations
of practitioners based on their uncontrolled
observations.
▪ A limitation is that present day means of non-
invasive detection of asymptomatic recurrence
were not available at the time of the CEA
Second-Look Trial. A recently reported rando-
mised controlled trial (FACS) in which regular
CEA and/or CT monitoring were compared with
minimum follow-up showed no survival advan-
tage associated with earlier detection through
monitoring.
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curative in under half of patients.4 Results had not
improved in several decades (Slack et al, 1982, unpub-
lished work).5 6 Reﬁnements in primary operative tech-
niques had not made a difference7 and it was
considered unlikely that technical modiﬁcations would
lead to improvement in survival following surgery.4 5
Routine surgical follow-up had not led to further
surgery being shown to be beneﬁcial: clinical evidence
of recurrence usually meant that the tumour would be
unresectable at second-look laparotomy.8 The published
experience of members of the Working Party who devel-
oped and launched the trial was that of 180 patients, fol-
lowed up from 6 months to 15 years, with a total of 2319
outpatient clinic visits, only 1 patient could be consid-
ered to have had a potentially curative second-look oper-
ation.9 They concluded that to re-resect with prospect of
beneﬁt, recurrence had to be detected before it was clin-
ically evident (Slack et al, 1982, unpublished work) but
more proactive clinical follow-up of asymptomatic
patients by three monthly sigmoidoscopy, barium enema
and chest X-ray (the methods available at the time) had
failed to show improvement in 5-year survival.10
Nevertheless, there had been several reports of 30%
5-year survival in selected patients after radical resection
of recurrent cancer6 11 12 and resection was believed to
sometimes lead to ‘cure’.6 11–13
Improving detection and treatment of recurrent disease:
the context in 1982
The trial development group considered the evidence
available at the time for methods of detecting recur-
rence early and a founding principle of the CEA
Second-Look Trial was that early detection of recurrent
tumour would only be justiﬁable if further treatment
offered the prospect of beneﬁt to the individual patient
(ﬁgure 1; Slack et al, 1982, unpublished work). The evi-
dence available to the trial working party in 1982 is out-
lined below.
The Wangensteen approach
During the 1950s the systematic use of a policy-based
second operation was reported. Patients at high risk of
recurrence (those with Dukes’ Stage C tumours) were
reoperated on at six-monthly intervals, resecting recur-
rence when found, until they were ‘tumour free’. If cancer
had been found the patients were scheduled for third and
more ‘looks’, up to six further abdominal operations,
‘before the abdomen was free of cancer’ (ﬁgure 2). Once
a patient had undergone a negative laparotomy, no more
surgery was recommended. Sixty-four patients with colon
or rectal cancer were managed in this way. In 35 (55%) of
them the ‘second-look’ laparotomy was negative for the
discovery of recurrent cancer, 7 of whom subsequently had
clinical recurrence. There were four (6%) operative
deaths.14 The Working Party concluded that this ‘blanket
second-look’ policy might have produced some ‘cures’ but
entailed high rates of negative laparotomy and an
unacceptable operative mortality rate (Slack et al, 1982,
unpublished work).
The CEA-prompted second-look approach
CEA had been shown to detect recurrence of colorectal
cancer following surgery.15–20 CEA rose, on average,
4 months prior to clinical evidence of recurrence16 and
there were reports of the use of serial serum CEA assays
to detect asymptomatic recurrences in the belief that
curative resection would be possible more frequently.15–17
Several groups used CEA in this way, and found low false-
positive rates8 21 and the resectability rate of recurrence
was higher than when clinical criteria were used to
prompt reoperation.8 In the largest published experience
of CEA in a postoperative monitoring role8 15 recurrent
tumour, which was resectable, was found in 70% in whom
reoperation was prompted by a rise in the serum CEA
compared with a quarter of patients undergoing second-
Figure 1 The ‘Working Party’ that produced the protocol in
1982 for the carcinoembryonic antigen Second-Look Surgery
Trial (Slack et al, 1982, unpublished work).
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look laparotomy prompted by clinical indications. Others
had not found CEA to be useful in this postoperative
monitoring role. Even if efﬁcacy of CEA-detected recur-
rence was accepted, there was still the unresolved ques-
tion of effectiveness: if more patients were detected and
there were more instances of resectable recurrence, did
that lead to better survival and patient beneﬁt? The con-
ﬂicting interpretations of observational data resulted in
calls for trials15 21 22 including one within a 1981 NIH
Consensus Statement.20
The objective of the CEA Second-Look Surgery Trial
was to determine whether, following potentially curative
primary surgery for colorectal cancer, mortality could be
decreased by a policy of second-look surgery prompted
by rising serum CEA. The trial ran from 1982 to 1993.
The main result, that there was no survival advantage,
was reported in 1994 to the British Oncological
Association23 and was published in a letter to the Journal
of the American Medical Association.1
Detection and reoperation for asymptomatic colorec-
tal cancer recurrence has since become routine in the
form of hepatic resection24 and pulmonary metastasect-
omy25 but without evidence from controlled trials for
either practice.26 27 When doubts were raised about the
security of the evidence in the BMJ in 200726 a general
belief existed that randomised controlled trials of the
effectiveness of resection of liver or lung metastases were
not possible and were not needed. These paired beliefs
are brought into question by the previously unpublished
CEA Second-Look Trial: a randomised trial had been
carried out and the presumed beneﬁt of surgery for
cancer recurrence was not seen.1 23
Closure of the trial in 1993 and gaining access to the data
in 2011
The RIAT restorative authors had been involved in various
studies related to surgery for disseminated colorectal
cancer26 28 29 including a conundrum as to whether discov-
ery of an elevated CEA assay should prompt, or be consid-
ered a contraindication to, pulmonary metastasectomy.30
We knew the CEA trial had been recruiting in the 1980s
but when we searched the literature for the result of the
trial we found nothing later than 1994.1 23 In 2009 we con-
tacted the chief investigator of the trial at the time of its
closure ( JMAN) and the present director of the University
College London Cancer Trials Centre ( JAL). We were
informed that the data were irretrievably lost. However,
KM was aware that CEA trial data were still in the depart-
ment and after further enquiries RCGR gained access to
anonymised electronic data in 2011. The process of data
restoration is described later. It was agreed that the trial
would be published as part of ‘RIAT’.2 3
Among the documents made available to the RIAT
restorative authors were listed the members of the trial
development group in the 1982 protocol (Slack et al,
1982, unpublished work) and the contributors to the
1994 manuscript (Northover J, Houghton J. Post opera-
tive CEA monitoring and second-look surgery in colorec-
tal cancer: the effect on survival measured using a
multicentre randomised trial (Manuscript), 6-7-1994,
unpublished work). None of these individuals expressed
an interest in resuming work on the trial or were in a pos-
ition to do so. When we contacted them later to share the
restored data with them no one raised any objection but
on the contrary encouraged us to publish their ﬁndings.
Figure 2 Illustration of operative
findings in six successive
operations seeking recurrence of
colorectal cancer.14
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METHODS
Trial intent and design
The recruitment intentions and the trial protocol as pre-
sented here are essentially as written in the manuscript
prepared in 1994 with the full intention of publishing
the trial (Northover and Houghton, 1994, unpublished
work). The text has been edited by the RIAT authors but
no new material has been introduced.
The CEA Second-Look Trial was intended to recruit at
least 2000 patients over 3 years and to follow them for
5 years. The study was speciﬁcally designed with late ran-
domisation in order to maximise statistical power. It was
originally intended to recruit 2000 patients with the
anticipation that about 25% would show a CEA rise as
the ﬁrst evidence of possible recurrence. This number
would have provided 95% power to detect an improve-
ment in 2-year survival from the second-look procedure
from 25% to 55% at α=0.05. The protocol stated that for
the trial to be stopped prematurely very stringent levels
of signiﬁcance (p<0.001) would be used. Analyses of the
randomised groups were to be by Kaplan-Meier lifetables
and the logrank test on ‘intention to treat’ (Northover
and Houghton, 1994, unpublished work).
Their intentions were explicitly set out as follows in
1981 (Slack WW, Public Health Service Grant
Application to NIH, 1981, personal communication):
So far as society in general is concerned, if CEA monitoring
is shown to be of beneﬁt in this study, then it will be a
powerful incentive to the great majority of surgeons who
see no obvious advantage in routine CEA monitoring to
adopt the technique; as colorectal cancer is the second
commonest killing cancer in the Western world, the bene-
ﬁts would thus be enormous. If, however, CEA monitoring
is shown to be of no long term therapeutic value then it
should cease to be used in its presently available form, and
patients will thereby be spared the ‘needless anxiety’22 of
premature knowledge of their impending death.
The CEA trial design (ﬁgure 3) was devised so that
clinical follow-up would remain unbiased, and allow spe-
ciﬁc evaluation of the role of CEA-indicated surgery in
the treatment of recurrent colorectal cancer. After
potentially curative surgery for colorectal cancer, all eli-
gible patients were to be monitored identically using
conventional clinical follow-up together with regular
CEA assay, performed centrally. Clinicians would not be
informed of the result. When a ‘signiﬁcant’ CEA rise was
recorded, patients were to be randomised by the Trials
Centre into either ‘Aggressive’ or ‘Conventional’ arms.
In the case of patients in the ‘Aggressive’ arm, the clin-
ician would immediately be informed of the CEA rise so
that the patient could be urgently screened to exclude
widespread metastatic disease or a non-malignant cause
for the CEA rise. If neither was found, and the patient
was medically ﬁt for operation, the protocol required
second-look surgery to locate and remove any treatable
recurrence. In the case of patients in the ‘Conventional’
arm, the clinician would not be informed of the
‘signiﬁcant’ CEA rise nor of the fact that they had been
randomised to not have the CEA rise revealed.
The primary outcome was survival based on death cer-
tiﬁcation through the Ofﬁce of Population Censuses and
Surveys (OPCS; now called the Ofﬁce for National
Statistics (ONS)). No subset analyses were planned.
The intention as stated in the protocol was that the trial
would produce
A. A deﬁnitive answer concerning the effectiveness of
CEA-prompted second-look surgery to improve
survival.
B. An accurate picture of the ‘lead time’ produced by
CEA compared to clinically indicated second-look
surgery.
C. Further data relating CEA levels to tumour histology
and topography.
D. A large database on the natural history of colorectal
cancer (Slack et al, 1982, unpublished work).
The RIAT restorative authors regard (A) and (B) as
planned analyses. The (C) and (D) statements give no
indication as to the precise nature of analyses that might
follow and are regarded as opportunities for explanatory
subset analyses which were not in the event carried out.
The conduct of the trial 1982–1993
The trial was coordinated (initially) from the Cancer
Research Campaign (CRC) Clinical Trials Centre at
King’s College Hospital. CEA assays were performed
using a radioimmunoassay technique at a single centre
at Charing Cross Hospital.
Selection of patients
All patients up to the age of 76 who had undergone a
potentially curative resection for adenocarcinoma of the
colon or rectum and who were ﬁt and willing to adhere
to the postoperative monitoring routine were eligible for
the study. Patients were excluded if there was evidence
of incurable distant spread, either preoperatively or
during the primary operation, or if the CEA level failed
to return to the normal range (<10 ng/mL) within
6 weeks of primary surgery. Patients who had previously
received treatment for other types of cancer, apart from
basal or squamous cell carcinoma of the skin or in situ
carcinoma of the cervix adequately cone biopsied, were
excluded from the study.
Management of the primary tumour
A preoperative blood sample for CEA assay was taken
from all patients with suspected colorectal adenocarcin-
oma who otherwise fulﬁlled the trial entry criteria. This
was a pragmatically designed study so surgeons were at
liberty to use their normal operative technique and to
employ preoperative or postoperative radiotherapy or
adjuvant chemotherapy as was seen ﬁt, however they
were asked to remain consistent regarding the treatment
used for any particular type of disease. If at laparotomy,
a potentially curative resection was performed and
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subsequent histology conﬁrmed the diagnosis of adeno-
carcinoma, the patient was given a full explanation of
the study and could be registered.
Consent
The 1982 protocol includes a consent form (Consent
form A) to be completed at registration and a further
form (Consent form B) for patients who were rando-
mised to a ‘Second-Look Laparotomy’. There was a
protocol amendment in which the word ‘cancer’ is to be
replaced throughout by ‘a growth’ (Slack et al, 1982,
unpublished work).
Baseline data
The surgeons carried out investigations to detect the
presence of synchronous colorectal tumours (benign
and malignant) and to exclude occult liver spread;
(usually barium enema examination and ultrasound or
CT of the liver). In addition, factors that could give
raised CEA levels in the absence of recurrent colorectal
cancer, such as chronic lung disease, cirrhosis, chronic
pancreatitis and chronic renal failure were excluded by
clinical questioning, chest X-ray, liver function tests,
blood urea and electrolytes. Smoking habits and alcohol
consumption were also recorded as heavy smoking or
drinking, or a change in these habits, can inﬂuence
CEA levels.
Monitoring of patients
Clinical follow-up of all patients continued in an identi-
cal manner (3 monthly for the ﬁrst 2 years and
6 monthly for the next 3 years) while blood for CEA
assay was drawn monthly for the ﬁrst 3 years and
3 monthly for the next 2 years. If the patient remained
well and the CEA was within normal limits as deﬁned by
a pretested algorithm, monitoring continued according
to the schedule.
CEA assay
Ten millilitres of whole blood were taken from each
patient. The serum was separated and sent to the Trials
Centre in special plastic phials. After logging receipt, the
samples were forwarded to the Medical Oncology
Department at Charing Cross Hospital for assay. The
results were returned to the Trials Centre for recording
and action if appropriate. This centralised system
ensured that all participating clinicians were kept blind
to the CEA results for their patients. It also ensured
quality control of the CEA assay as there was no possibil-
ity of interlaboratory variation.
Serum CEA values were measured by double antibody
radioimmunoassay.31–33 A bank of serum samples has
been retained at −20°C.
Monitoring assay compliance prerandomisation
Throughout the trial, compliance with blood sampling
was monitored by the secretariat. Clinicians were
reminded each month of the patients for whom samples
were due; those who had missed the previous visit were
highlighted as urgent. The percentage compliance for
each participating patient was calculated as the number
of samples received divided by those expected ×100. The
median time between samples was also calculated.
Failure to achieve 50% of the expected samples was
deﬁned as poor compliance. Since the sensitivity to
detect CEA rise in such patients was greatly reduced
they were excluded from randomisation.
‘Significant’ rises in CEA
A rise in CEA was deﬁned as ‘signiﬁcant’ when the CEA
level was greater than 10 ng/mL on two successive occa-
sions and one of the following conditions was also met:
the CEA level was greater than 20 ng/mL on each of
two successive occasions or the level was rising and the
highest value was more than 7 ng/mL above the lowest
value ever recorded. If a ‘signiﬁcant’ rise in CEA
occurred, the record of the patient was reviewed at the
Trials Centre and provided no evidence of suspected
colorectal or other disease was recorded in the CRF, the
patient was randomised either into an ‘Aggressive’ or
‘Conventional’ arm (ﬁgure 4).
Randomisation
Patients were randomised equally between the two arms
(1:1). Patients whose compliance was between 50% and
70% or whose immediate postoperative sample had not
been received within the 4–6-week guideline were rando-
mised in a separate stratum. Randomisation was also
stratiﬁed by participating clinician. A block size of two
was used in order to maintain as close a balance as pos-
sible between the two treatment arms.
If the patient was randomised to the ‘Aggressive’ arm
the clinician was informed of the rise immediately by
telephone from the trial centre and subsequently in
writing and was requested to contact the patient
urgently. Patients were informed of their situation
including the fact that they had been randomised within
the trial to undergo a second-look procedure. This was
then undertaken if the patient gave written informed
consent. The surgeon carried out a full clinical workup
to exclude the possibility of a non-malignant cause for
the CEA rise (eg, change in smoking or drinking habit)
and to identify any incurable distant spread. In the
absence of these conditions the surgeon undertook a
mini-laparotomy, proceeding to full laparotomy with
macroscopic clearance of disease, should this be
possible.
For patients randomised to the ‘Conventional’ arm no
further action was taken; the clinician was neither
informed that the CEA had risen nor that the patient
had been randomised.
If at any stage a patient in the study developed clinical
evidence of recurrent disease the clinician was at liberty
to manage the patient according to usual practice. If the
Treasure T, Monson K, Fiorentino F, et al. BMJ Open 2014;4:e004385. doi:10.1136/bmjopen-2013-004385 5
Open Access
 group.bmj.com on June 19, 2014 - Published by bmjopen.bmj.comDownloaded from 
disease was in the abdomen and was thought to be treat-
able by a second-look operation with re-resection, this
was acceptable. By the nature of the trial design, the
clinician was blind as to whether such patients had been
randomised to the ‘Conventional’ arm of the trial or
had not been randomised because the CEA had failed
to denote the presence of recurrent disease.
Second-look laparotomy
The surgeon was expected to perform a thorough inspec-
tion of the abdominal cavity to locate any recurrent disease.
Initially a mini-laparotomy was performed; if widespread
tumour was detected all that was required prior to closure,
was biopsy. Otherwise following a full excision, bimanual
palpation of the old scar, inspection and palpation of the
Figure 3 Flow diagram of the Second-Look Surgery Trial from the 1982 protocol (Slack et al, 1982, unpublished work).
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pelvic cavity, the small bowel, the mesentery, the retroperito-
neum, the colon and rectum and the anastomosis was
undertaken. The liver was fully mobilised to determine
whether any tumour was present. Detailed dissection of the
pelvic and retroperitoneal areas and therapeutic resection
were then carried out with the objective of total extirpation
of all recurrence. Complete data recording of the proced-
ure along with the results of the histology of all potentially
involved sites was required by the trial’s ofﬁce.
For patients in whom a radical resection was achieved
after second-look surgery (motivated either on clinical
information or because the patient had been rando-
mised to the ‘Aggressive’ arm) the follow-up schedules
for clinical examination and blood sampling reverted to
those following the primary operation. However, for
patients randomised to the ‘Aggressive’ arm, clinicians
were immediately notiﬁed of any further CEA levels
above 10 ng/mL.
Figure 4 Decision-making algorithm for CEA to trigger second-look surgery.14
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Death
Every patient registered onto the study was ‘ﬂagged’
with the OPCS (now ONS) which provides automatic
notiﬁcation of date of death. This enabled the trial
centre to receive certiﬁed cause of death for all patients.
Trial oversight
A Data Monitoring Sub-Committee (DMSC) composed
of Working Party members not entering patients into
the trial was asked to review the data after the ﬁrst 100
patients had been randomised, which occurred in
January 1988, and again after 200 patients had been ran-
domised in February 1993. At this point it was recom-
mended by the Data Monitoring Committee that the
trial be stopped since it was very unlikely that any clinic-
ally important advantage would be demonstrated for
patients undergoing second-look surgery.
Methods of the RIAT process
Data
The RIAT restorative authors had been warned by the
statisticians called in to look at the data in 2003–2004
that ‘the databases were corrupted with key variables no
longer abstractable’ (McConkey C. Chris McConkey
e-mail 1 October 2009, unpublished work and Gray
R. Richard Gray e-mail 1 October 2009, unpublished
work). We found that the data on paper and on ﬁle
were accessible and we had no reason to doubt the ver-
acity of individual items. We found that the electronic
ﬁles had numerous problems with formatting which
made the ﬁles on the 1447 individual patients difﬁcult
to handle but that the data entries were not themselves
corrupted.
One of the RIAT restorative authors (KM) had worked
in the Trials Centre during the time the CEA trial data
were being accrued and knew the systems in use and
their changes but was not directly involved in this trial at
any stage.
The questions raised and the problems encountered
were resolved as follows:
▸ The codes indicating that a patient had met the cri-
teria for CEA elevation and whether they were rando-
mised to ‘Aggressive’ or ‘Conventional’ arm were
preserved and tallied with the number in the 1994
manuscript (Northover and Houghton, 1994, unpub-
lished work).
▸ There were variations in the way dates were recorded
in the database. There had been migrations of data
from a ‘Prime’ server using ‘Universe’ to ‘Excel’ and
the interpretation of the present authors, with infor-
mation from contemporary witnesses was that in
undertaking the task operators did not always cor-
rectly specify these data as ‘dates’ when importing,
and/or allowed them to be converted to American
date formats. These errors prevented calculations and
would have defeated running a survival analysis
without correction of the ﬁle entries. The dates were
however visually readable and not ‘corrupt’. Some
could be corrected by running current versions of
software. Others were manually corrected by
re-entering them in a Microsoft date format. Paper
records were available to resolve uncertainties.
▸ The next problem was in linking these three groups
of patients (randomised to ‘Aggressive’, randomised
to ‘Conventional’ and not randomised) to the dates
for survival analysis. Individual patients were uniquely
identiﬁed in the ﬁles by seven digit strings to which
letters had been added at the beginning and end,
possibly for trial administrators’ checklists or sub-
group identiﬁcation. Once we had established that
the initial and terminal letters were redundant for
analysis of the primary endpoint, we were able to
write the code to restore the seven digit strings.
▸ It was evident that the seven digits did not represent
a simple sequence but certain positions identiﬁed
particular characteristics, such as participating centre.
We recognised a consistent pattern of mismatch in
the fourth digit, a zero in one ﬁle was an eight in the
other with all other digits remaining the same. It was
suggested to us that the fourth digit replacement was
used to identify patients suitable for post hoc sub-
group analyses but no documentation was found to
conﬁrm this. By checking back to the dates of birth
we were able to conﬁrm that this systematic correc-
tion resolved the problem and most of the data were
then usable.
▸ By ranking all the data in the paired ﬁles for line by
line visual inspection residual discrepancies were
identiﬁed. Scrutinising the digit strings allowed for
seven of the remaining eight pairs to be reconciled
and veriﬁed on dates of birth. We failed to resolve
only 1 of 1447 records in each ﬁle. This patient had
not been randomised.
▸ Inspection of the accrual of death dates was discon-
tinuous for a couple of years suggesting a lapse in
either recovery or entry. The current trials centre
obtained permission to re-run the ONS search in July
2012.
In summary, we identiﬁed several problems but they
were systematic and not random (we would not use the
value-laden word ‘corrupted’). We were able to rectify
the formatting errors and verify that the data used for
our analysis were correct. The Kaplan-Meier analysis was
re-run.
RESULTS
The original main results 1994
The study opened to recruitment in November 1982
and was closed by the Working Party, on the acceptance
of a recommendation from the DMSC, on 17 February
1993. During this period 1447 patients were registered
by 73 participating clinicians in 58 hospitals in the UK.
Of these 39 (2.7%) were deemed ineligible since their
CEA did not fall below 10 ng/mL by 6 weeks after
surgery. A further 173 patients were excluded from
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analysis; 4 did not have a conﬁrmed diagnosis of adeno-
carcinoma, 6 were considered unﬁt for continued moni-
toring, 4 had a previous and 1 a simultaneous
non-colorectal malignancy, 2 had metastatic disease and
156 (10.8%) never complied with the requirement for
monthly blood sampling or only did so for 3 months or
less (ﬁgure 5).
Of 1235 patients who continued in the trial, 80%
achieved a greater than 60% compliance with blood
sampling, while 12.5% registered between 40% and 59%
of the required samples and only 7.5% had compliance
of less than 40% The majority of randomisations (160/
216; 74%) were prior to the second anniversary of the
primary diagnosis. Three patients randomised had prior
recurrent1 or metachronous (Slack et al, 1982, unpub-
lished work) disease detected clinically, without a rise in
CEA and were operated on.
Two hundred and sixteen patients developed a ‘signiﬁ-
cant’ rise in CEA and as no recurrent disease had been
recorded at their latest trial follow-up, they were rando-
mised by the Trial Ofﬁce (108 to each arm). The
median time from primary surgery to randomisation was
403 days, (range 103–1754) with no statistical difference
between the two groups (Northover and Houghton,
1994, unpublished work).
The characteristics of patients in the two groups are
given in table 1.
The stage mix of 980 patients who were eligible for
inclusion in the randomised trial but who did not have a
CEA rise as deﬁned was Dukes’ A 15.1%, B 55.2%, C1
23.3%, C2 6.4%.
Of the patients randomised to the ‘Aggressive’ arm 83
(77%) had recurrent cancer identiﬁed and 62 (57%)
patients had ‘second-look’ surgery. In patients rando-
mised to the ‘Conventional’ arm 89 (82%) had
developed recurrent disease by the date of analysis. In
26 (24%) of these patients second-look procedures
were undertaken. By February 1993, 91/108 in the the
‘Aggressive arm’ had died and 88/108 patients had died
in the ‘Conventional’ arm (relative risk=1.16, 95% CI
0.87 to 1.37) (Northover and Houghton, 1994, unpub-
lished work). It was considered by the data monitoring
committee to be ‘highly unlikely that any survival advan-
tage would be demonstrated for patients undergoing
second-look surgery’. This was communicated to the
chief investigator.
RIAT restoration and updated survival analysis
The data were restored by the RIAT authors for 1446 of
1447 patients to the extent that the RIAT authors were
conﬁdent of their dates of birth, death and whether
they met criteria for entry into the controlled trial and
then to which arm they were allocated.
The electronic records were intact with respect to the
identity of the patients, which patients had reached the
criteria for randomisation, and the trial arm to which
they had been randomly allocated for all 216 patients
who were randomised. The sex, age, primary site and
Dukes’ stage as recorded in the 1994 manuscript are
shown in table 1.
Certiﬁcation of death was obtained from ONS on
behalf of the RIAT restorative authors for 204 of 216 ran-
domised patients who died between 17 October 1983
and 8 September 2011. There were equal numbers of
patients in the two arms (108) and equal numbers of
death dates were retrieved (102). We also have dates of
death in 862 of the 1230 patients who were not rando-
mised. Kaplan-Meier analysis in these three groups is
shown in ﬁgure 6, showing survival of the 1230
Figure 5 Flow chart of enrolled
and ultimately randomised
patients. ‘Blind’ in the bottom left
box means that the clinical teams
were unaware of the elevated
carcinoembryonic antigen
discovered and were unaware
that the patients have been
randomised. They were
indistinguishable among the 1230
non-randomised patients who
were being followed up (see
figure 6).
Treasure T, Monson K, Fiorentino F, et al. BMJ Open 2014;4:e004385. doi:10.1136/bmjopen-2013-004385 9
Open Access
 group.bmj.com on June 19, 2014 - Published by bmjopen.bmj.comDownloaded from 
participants who entered the trial but were not rando-
mised and the 108 participants randomised into each
arm.
The lead time conferred by CEA monitoring, deﬁned
as the median time to clinically detected disease for
patients randomised to the ‘Conventional’ arm, was
323 days (95% CI 203 to 443). This analysis included
censored observations on 23 patients, however only 5 of
these had a censored time less than the lead time. It was
regarded as unlikely, therefore, that the lead time would
decrease as further events occur. The analysis presented
to the British Oncological Association in 1994 showed
that at 3, 6 and 12 months the CEA versus clinical detec-
tion rates for recurrence were 88% vs 18%, 95% vs 44%
and 97% vs 70%. The RIAT authors did not repeat this
analysis.
DISCUSSION
We have restored data sufﬁcient to achieve the primary
outcome of interest as speciﬁed by the CEA trialists:
Does a policy of CEA-prompted second-look surgery fol-
lowing ‘curative’ resection of colorectal cancer produce a
decrease in morbidity and mortality due to tumour recur-
rence, despite sequelae of second look surgery?
The answer is that acting on CEA elevation by second-
look surgery did not reduce mortality compared with
patients in whom similar CEA elevation remained
unknown. This negative ﬁnding led to the closing of the
trial in 19941 23 and we conﬁrm it here. There was a
small non-signiﬁcant excess of deaths in the ‘Aggressive’
arm. The burden of morbidity attributable to the
greater number of investigations and operations was not
captured by the trial protocol nor indeed the ‘needless
anxiety’ which concerned Moertel et al22 and the
authors of the CEA trial protocol (Slack et al, 1982,
unpublished work).
The second planned analysis was to obtain an accurate
picture of the ‘lead time’ produced by CEA compared
to clinical pick up of patients with recurrence. CEA
monitoring did pick up patients considerably sooner
than the clinical methods available at the time by
11 months (95% CI 7 to 14 months).
CEA monitoring for the purpose of early detection of
asymptomatic cancer is currently recommended at least
every 6 months in the ﬁrst 3 years. In addition a
minimum of two CT scans are recommended in the ﬁrst
3 years.34 The FACS trial, recently reported, has also
shown no survival advantage from CEA monitoring com-
pared with minimum follow-up.35 More operations were
performed with ‘curative intent’ for recurrent cancer in
those having more intensive monitoring and there were
more deaths (18.2% (164/901) vs 15.9% (48/301); dif-
ference, 2.3%; 95% CI −2.6% to 7.1%). These results
are similar to the ﬁndings in the CEA trial. Although
the phrase ‘curative intent’ occurs about 40 times in the
manuscript, better survival was not achieved with any of
the three monitoring schedules compared with
minimum follow-up.
The third and fourth intentions set out by the CEA tri-
alists were (C) to obtain further data relating CEA levels
to tumour histology and topography and (D) a large
database on the natural history of colorectal cancer.
Multiple CEA assay results exist in the data we hold for
1446 patients and it would be possible to link these to
survival as a result of the RIAT restorative work.
With respect to the natural history of colorectal cancer
although we trust the death certiﬁcation data for the
date of death it has been shown that ‘at least a third of
all death certiﬁcates are likely to be incorrect’.36 No
Table 1 Age, sex and colorectal cancer stage of 216
randomised patients
Aggressive
N=108
Conventional
N=108
Sex male (%) 60 (56%) 68 (63%)
Age years, median
and range
64 (33–75) 62 (35–75)
Pathological stage N (%) N (%)
Dukes’ A 5 (4.6) 5 (4.6)
Dukes’ B 46 (42.6) 49 (45.4)
Dukes’ C1 36 (33.3) 38 (35.2)
Dukes’ C2 17 (15.7) 10 (9.3)
Missing 4 (3.7) 6 (5.6)
Figure 6 Survival from date of recruitment into the
carcinoembryonic antigen (CEA) Second-Look Trial (N=1446)
following potentially curative colorectal cancer surgery.
Patients who had CEA elevation according to the trial criteria
(N=216) were randomly allocated in equal groups to have
CEA revealed to their surgeons (red) or concealed (blue).
Date of death was confirmed from Office for National Statistics
in 104/108 in each arm. The green line is for all other patients.
Some (N=862 of 1230) would have had clinically evident early
recurrence precluding randomisation. The initial plateau is an
illustration of a death-free interval44 or ‘immortal time bias’45
Patients in prospective studies may have a built in obligatory
survival time from some starting point in order to attain the
requirements to be included in the data set. This is an artefact
but may be absorbed into survival time adding to and not
readily distinguished from survival time attributed to treatment.
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doubt aware of this and seeking much more detailed
information, the CEA trialists had asked for detailed
postmortem examinations.
It appears that it was disagreement concerning
explanatory analyses which contributed to the failure to
publish the primary outcome of interest (Northover and
Houghton, 1994, unpublished work). The purpose of
such analyses would be to discover subsets of patients in
whom there was a beneﬁt from the intervention under
evaluation and to thus determine the characteristics of
patients in whom the intervention might have had a
beneﬁcial effect by analysis of mediators and modera-
tors.37 There is a general objection to this exercise
because it can lead to spurious associations.38 39
Furthermore when there is no overall beneﬁt found, as
in the CEA Second-Look Trial, any subgroup(s) where
there is a positive association between intervention and
outcome must be balanced by one or more other
groups where there was net harm. The methods section
of the 1994 manuscript states ‘Subgroup analyses have
been performed to address speciﬁc issues but these
need to be interpreted with appropriate caution’
(Northover and Houghton, 1994, unpublished work). In
the event no completed subset analyses were in the 1994
paper and the closing notes between the authors are on
the matter of a subset analysis. We have not attempted
any in restoring the trial.
The answer to the primary research question was clear
in 1993 and was the explicit reason for stopping the
trial: it was improbable that a beneﬁt from CEA
prompted second-look surgery had been missed and in
the absence of beneﬁt there was net harm being done
to the patients. The forms of second-look surgery now
widely practiced in colorectal cancer are liver and lung
resection of metastases.
▸ Full mobilisation of the liver at second-look laparot-
omy was included in the CEA trial protocol. Hepatic
resection has entered routine practice based on
observational data40 and an opportunity to do a ran-
domised trial, for which a power calculation was pro-
posed in 1992 from the Mayo Clinic,41 was not
taken.24
▸ Two patients had a thoracotomy prompted by CEA
elevation. Pulmonary metastasectomy for colorectal
cancer is, after primary lung cancer, the second com-
monest thoracic cancer operation and is the subject
of an ongoing randomised controlled trial.42
The CEA trial ﬁndings have been corroborated by the
larger FACS trial. If the CEA trial results had been made
available in 1994, and there is no evident reason why
they should not have been, a more critical scrutiny of
the evidence base that was used to bring liver and lung
metastasectomy into practice24 29 might have been
undertaken. The CEA trial was a well-conceived and
meticulously executed randomised trial and we hope
that publishing it now more than 20 years after its com-
pletion will indicate the possibility of more randomised
trials in surgery.43
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